Skip to main content
. 2019 Sep 20;10:1014. doi: 10.3389/fneur.2019.01014

Table 1.

Demographics, clinical, and imaging characteristics of MSA and control subjects.

MSA-total MSA-P MSA-C Controls MSA-total
vs.
controls (p)
MSA-P
vs.
MSA-C (p)
MSA-P
vs.
controls (p)
MSA-C
vs.
controls (p)
Agea 58.70 ± 6.85 59.00 ± 7.19 58.15 ± 6.27 60.48 ± 6.42 0.341 0.727 0.479 0.316
Gender (M:F)b 12:25 7:17 5:8 12:9 0.097 0.716 0.075 0.481
Disease duration (months)a 26.57 ± 13.03 27.54 ± 12.76 24.77 ± 13.57 . 0.547
UPDRS-IIIc 33.62 ± 11.78 37.92 ± 10.95 25.69 ± 8.88 . 0.002*
UMSARS-IIc 21.84 ± 5.43 23.50 ± 5.32 18.77 ± 4.24 . 0.013*
HandY staged 2.99 ± 0.58 3.06 ± 0.62 2.85 ± 0.46 0.369
Visual rating (0/1/2/3) b
Right side 7/13/12/5 1/7/11/5 6/6/1/0 20/1/0/0 < 0.001* 0.001* < 0.001* 0.002*
Left side 9/11/8/9 3/5/7/9 6/6/1/0 20/1/0/0 < 0.001* 0.004* < 0.001* 0.002*
Visual category (non-higher/
higher grade) b
Right side 20/17 8 /16 12/1 21/0 < 0.001* 0.001* < 0.001* 0.382
Left side 20/17 8 /16 12/1 21/0 < 0.001* 0.001* < 0.001* 0.382
Putaminal R2*e
Right side 28.49 ± 6.24 30.37 ± 6.83 25.01 ± 2.65 25.19 ± 3.10 0.008* < 0.001* 0.001* 0.903
Left side 25.79 ± 5.08 27.05 ± 5.78 23.48 ± 2.07 24.14 ± 3.26
Putaminal volumef
Right side 3844.61 ± 928.98 3455.83 ± 729.21 4562.35 ± 842.31 5221.04 ± 609.86 < 0.001* < 0.001* < 0.001* 0.004*
Left side 4168.55 ± 1055.35 3739.57 ± 932.02 4960.52 ± 793.00 5464.26 ± 678.12

UPDRS-III = Unified Parkinson's Disease Rating Scale part III; UMSARS-II = Unified Multiple System Atrophy Rating Scale part II; HandY stage = Hoehn and Yahr stage;

= categorization of visual rating (0 or 1 = non-higher category; 2 or 3 = higher category).

a

Independent t-test;

b

Chi-square test or Fisher's exact test;

c

Analysis of Covariance (ANCOVA) test, covariated with age, gender, and disease duration;

d

Mann-Whitney U-test;

e

General Estimating Equation (GEE) covariated with age, sex and image side;

f

GEE covariated with age, sex, total intracranial volume and image side;

pUncorrected p-values for multiple testing;

*

Statistically significant after Bonferroni correction.